Archive: 03/12/2021

zetagen logo

CNYBAC Client Zetagen Therapeutics receives FDA Breakthrough Device Designation for ZetaMet

ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers 1 December 2021 [Zetagen Press Release] US Food and Drug Administration: The technology is a first-of-its kind molecular pathway designed to suspend cancer, i...
CNYBAC Client Zetagen Therapeutics receives FDA Breakthrough Device Designation for ZetaMet